Document Detail


Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.
MedLine Citation:
PMID:  10636157     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The authors conducted a pilot randomized, double-blind, placebo-controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated cognitive impairment. Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study.
Authors:
N Sacktor; G Schifitto; M P McDermott; K Marder; J C McArthur; K Kieburtz
Related Documents :
22348897 - Iron supplementation for the treatment of chronic heart failure and iron deficiency: sy...
15817917 - Mini-mental state examination is superior to plasma glucose concentrations in monitorin...
19610477 - What the heart thinks, the tongue speaks: a study on depression and lexical choice.
12730257 - Additive effects of cognitive function and depressive symptoms on mortality in elderly ...
10100827 - Emotional expression and feeling in schizophrenia: effects of specific expressive behav...
17151807 - The effect of oral alpha-galactosidase on intestinal gas production and gas-related sym...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Neurology     Volume:  54     ISSN:  0028-3878     ISO Abbreviation:  Neurology     Publication Date:  2000 Jan 
Date Detail:
Created Date:  2000-01-27     Completed Date:  2000-01-27     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  233-5     Citation Subset:  AIM; IM; X    
Affiliation:
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA. sacktor@jhmi.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Cutaneous
Adult
Cognition Disorders / virology*
Female
HIV Seropositivity / physiopathology,  psychology*
Humans
Male
Mental Recall / drug effects
Middle Aged
Monoamine Oxidase Inhibitors / administration & dosage*,  adverse effects,  therapeutic use
Motor Activity / drug effects
Pilot Projects
Placebos
Psychomotor Performance / drug effects
Selegiline / administration & dosage*,  adverse effects,  therapeutic use
Verbal Learning
Grant Support
ID/Acronym/Agency:
RR00044/RR/NCRR NIH HHS; RR00645/RR/NCRR NIH HHS; RR00722/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Monoamine Oxidase Inhibitors; 0/Placebos; 14611-51-9/Selegiline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.
Next Document:  Relating axonal injury to functional recovery in MS.